RS16804A - Upotreba 4-piridilmetilftalazina u lečenju raka - Google Patents

Upotreba 4-piridilmetilftalazina u lečenju raka

Info

Publication number
RS16804A
RS16804A YUP-168/04A YUP16804A RS16804A RS 16804 A RS16804 A RS 16804A YU P16804 A YUP16804 A YU P16804A RS 16804 A RS16804 A RS 16804A
Authority
RS
Serbia
Prior art keywords
pyridylmethyl
phthalazine
day
chloroanilino
compound
Prior art date
Application number
YUP-168/04A
Other languages
English (en)
Serbian (sr)
Inventor
Margaret Han Dugan
Jeanette Marjorie Wood
Original Assignee
Novartis Ag.,
Novartis Pharma Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag.,, Novartis Pharma Gmbh., filed Critical Novartis Ag.,
Publication of RS16804A publication Critical patent/RS16804A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YUP-168/04A 2001-09-12 2002-09-11 Upotreba 4-piridilmetilftalazina u lečenju raka RS16804A (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33102501P 2001-09-12 2001-09-12
US31869401P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12
PCT/EP2002/010194 WO2003022282A1 (en) 2001-09-12 2002-09-11 Use of 4-pyridylmethylphthalazines for cancer treatment

Publications (1)

Publication Number Publication Date
RS16804A true RS16804A (sr) 2007-02-05

Family

ID=27502161

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-168/04A RS16804A (sr) 2001-09-12 2002-09-11 Upotreba 4-piridilmetilftalazina u lečenju raka

Country Status (22)

Country Link
US (2) US20040258770A1 (OSRAM)
EP (1) EP1427420B1 (OSRAM)
JP (1) JP2005502690A (OSRAM)
KR (1) KR20040029172A (OSRAM)
CN (1) CN1330308C (OSRAM)
AT (2) ATE421880T1 (OSRAM)
AU (2) AU2002342678B2 (OSRAM)
BR (1) BR0212446A (OSRAM)
CA (1) CA2457848A1 (OSRAM)
CO (1) CO5560545A2 (OSRAM)
CY (1) CY1105189T1 (OSRAM)
DE (2) DE60212415T2 (OSRAM)
DK (1) DK1427420T3 (OSRAM)
ES (2) ES2320922T3 (OSRAM)
HR (1) HRP20040241A2 (OSRAM)
IL (1) IL160382A0 (OSRAM)
NO (1) NO327358B1 (OSRAM)
NZ (1) NZ531484A (OSRAM)
PL (1) PL367349A1 (OSRAM)
PT (1) PT1427420E (OSRAM)
RS (1) RS16804A (OSRAM)
WO (1) WO2003022282A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69533057T2 (de) * 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
EP0885198B1 (en) * 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
NO327358B1 (no) 2009-06-15
AU2006203428B2 (en) 2009-06-04
DE60212415T2 (de) 2006-11-23
ES2266590T3 (es) 2007-03-01
ATE329597T1 (de) 2006-07-15
DK1427420T3 (da) 2006-10-02
EP1427420A1 (en) 2004-06-16
CN1330308C (zh) 2007-08-08
PL367349A1 (en) 2005-02-21
HRP20040241A2 (en) 2005-04-30
JP2005502690A (ja) 2005-01-27
CO5560545A2 (es) 2005-09-30
DE60231068D1 (de) 2009-03-19
NZ531484A (en) 2007-02-23
BR0212446A (pt) 2004-08-17
NO20040973L (no) 2004-06-03
DE60212415D1 (de) 2006-07-27
AU2006203428A1 (en) 2006-08-31
ATE421880T1 (de) 2009-02-15
WO2003022282A1 (en) 2003-03-20
CY1105189T1 (el) 2010-03-03
IL160382A0 (en) 2004-07-25
US20090196871A1 (en) 2009-08-06
CN1553803A (zh) 2004-12-08
US20040258770A1 (en) 2004-12-23
EP1427420B1 (en) 2006-06-14
ES2320922T3 (es) 2009-05-29
PT1427420E (pt) 2006-10-31
AU2002342678B2 (en) 2006-08-24
CA2457848A1 (en) 2003-03-20
KR20040029172A (ko) 2004-04-03

Similar Documents

Publication Publication Date Title
Andrikopoulou et al. The emerging role of capivasertib in breast cancer
JP2021138704A (ja) 神経膠芽腫の治療のための併用療法
HUE027516T2 (en) Combination therapy with an antitumor alkaloid
KR20180129918A (ko) 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
US12116363B2 (en) Combinations for immune-modulation in cancer treatment
US20090196871A1 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
AU2011323832B2 (en) Method of treating neuroendocrine tumors
Reck et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study
MX2008014292A (es) Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
RU2346686C2 (ru) Комбинации, включающие эпотилоны и антиметаболиты
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
Kerr et al. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer
AU2002342678A1 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
RU2320344C2 (ru) Применение 4-пиридилметилфталазинов для лечения рака
EP1712234A1 (en) Use of 4-Pyridylmethylphthalazines for Cancer Treatment
Hofheinz et al. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin-refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO)
NZ552119A (en) Use of a 4-pyridylmethylphthalazines for renal cancer treatment
ZA200401184B (en) Use of 4-pyridylmethylphthalazines for cancer treatment.
Mavroudis et al. Sequential administration of cisplatin–etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study
US20030139430A1 (en) Use of organic compounds
JP6239745B2 (ja) がんの処置のための、ｒｏ５５０３７８１及びカペシタビンの組み合わせ
CN119816307A (zh) 包含flt3抑制剂的癌症组合疗法
UA78969C2 (en) 4-pyridylmethyl-phthalazine anti-angiogenesis agents combined with platinum compound and/or antitumor metabolite, pharmaceutical composition for treating proliferation-associated diseases
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
Li Chemotherapy for Gynecologic Cancer Quan Li and Jack L. Watkins Chemotherapeutic Agents in Gynecologic Oncology